Jacobs R H, Lal S M, Nolph K D
Division of Nephrology, University of Missouri Health Sciences Center, Columbia.
Adv Perit Dial. 1993;9:288-90.
Increased incidence of cardiovascular morbidity and mortality has been observed in continuous ambulatory peritoneal dialysis (CAPD) patients. Hyperlipemia is an important etiologic factor in the pathogenesis of coronary artery disease. Lovastatin has been shown to effectively lower both the serum total cholesterol and triglyceride levels, the most common abnormalities in these patients. In a retrospective study we assessed the lipid-lowering effects of lovastatin (20 mg/day) in 8 CAPD patients whose serum cholesterol and/or triglycerides remained greater than 240 mg/dL, despite a low cholesterol diet. At 6 months of lovastatin therapy, moderate reductions in total cholesterol and triglyceride levels were observed in 2 patients. Although 20 mg/day of lovastatin were well tolerated, the treatment was not universally effective in lowering the serum cholesterol and triglyceride levels.
在持续非卧床腹膜透析（CAPD）患者中，已观察到心血管发病率和死亡率增加。高脂血症是冠状动脉疾病发病机制中的一个重要病因。洛伐他汀已被证明能有效降低血清总胆固醇和甘油三酯水平，而这是这些患者最常见的异常情况。在一项回顾性研究中，我们评估了洛伐他汀（20毫克/天）对8名CAPD患者的降脂效果，这些患者尽管采用了低胆固醇饮食，但其血清胆固醇和/或甘油三酯仍高于240毫克/分升。在洛伐他汀治疗6个月时，2名患者的总胆固醇和甘油三酯水平有适度降低。尽管20毫克/天的洛伐他汀耐受性良好，但该治疗在降低血清胆固醇和甘油三酯水平方面并非普遍有效。
